ATE303148T1 - Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden - Google Patents

Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden

Info

Publication number
ATE303148T1
ATE303148T1 AT98926193T AT98926193T ATE303148T1 AT E303148 T1 ATE303148 T1 AT E303148T1 AT 98926193 T AT98926193 T AT 98926193T AT 98926193 T AT98926193 T AT 98926193T AT E303148 T1 ATE303148 T1 AT E303148T1
Authority
AT
Austria
Prior art keywords
withdrawal
compounds
disclosed
withdrawal syndrome
brain damage
Prior art date
Application number
AT98926193T
Other languages
English (en)
Inventor
Boris Tabakoff
Lawrence Snell
Paula L Hoffman
Original Assignee
Lohocla Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohocla Res Corp filed Critical Lohocla Res Corp
Application granted granted Critical
Publication of ATE303148T1 publication Critical patent/ATE303148T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98926193T 1997-06-06 1998-06-05 Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden ATE303148T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4884897P 1997-06-06 1997-06-06
PCT/US1998/011312 WO1998055125A1 (en) 1997-06-06 1998-06-05 Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage

Publications (1)

Publication Number Publication Date
ATE303148T1 true ATE303148T1 (de) 2005-09-15

Family

ID=21956770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98926193T ATE303148T1 (de) 1997-06-06 1998-06-05 Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden

Country Status (5)

Country Link
EP (1) EP1011676B1 (de)
AT (1) ATE303148T1 (de)
AU (1) AU7808898A (de)
DE (1) DE69831416T2 (de)
WO (1) WO1998055125A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
US7378524B2 (en) 2003-04-11 2008-05-27 Taigen Biotechnology Co., Ltd. Aminoquinoline compounds
EP1951238A4 (de) * 2005-10-07 2014-07-09 Lohocla Res Corp Verfahren zur behandlung chronischer schmerzen
WO2015195943A1 (en) 2014-06-20 2015-12-23 Lohocla Research Corporation Multifunctional aminoquinoline therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) * 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5606063A (en) * 1991-02-27 1997-02-25 Merrell Pharmaceuticals Inc. NMDA antagonists
US5493027A (en) * 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof

Also Published As

Publication number Publication date
EP1011676A1 (de) 2000-06-28
DE69831416T2 (de) 2006-06-14
DE69831416D1 (de) 2005-10-06
WO1998055125A1 (en) 1998-12-10
EP1011676A4 (de) 2004-08-11
EP1011676B1 (de) 2005-08-31
AU7808898A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
CY1105370T1 (el) Μεθοδος θepαπειας των κλιμακτηριακων διαταραχων στις εμμηνοπαυσιακες και μετεμμηνοπαυσιακες γυναικες
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
IT1282353B1 (it) Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
BR0115910A (pt) Compostos orgânicos
DE69620241D1 (de) Gonadotropin releasing hormon- antagonisten
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
RU2002105377A (ru) Ксенон-антагонист nmda
DK0828727T3 (da) Cyclohexyldihydrobenzofuraner
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
ATE303148T1 (de) Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden
BG106748A (en) Method and compositions for treating pulmonary diseases
CO5690571A2 (es) Combinacion sinergica que comprende roflumilas y (r,r)-formoterol
AR008083A1 (es) Composiciones farmaceuticas y el uso de compuestos para preparar medicamentos para tratar desordenes del snc.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE382357T1 (de) Analgetikum für neugeborene und föten
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties